Evidence of a Specific Interaction between New Synthetic Antisepsis Agents and CD14
- 23 November 2009
- journal article
- research article
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 48 (51) , 12337-12344
Abstract
Synthetic molecules derived from natural sugars with a positively charged amino group or ammonium salt and two lipophilic chains have been shown to inhibit TLR4 activation in vitro and in vivo. To characterize the mechanism of action of this class of molecules, we investigated possible interactions with the extracellular components that bind and shuttle endotoxin [lipopolysaccharide (LPS)] to TLR4, namely, LBP, CD14, and MD-2. Molecules that inhibited TLR4 activation inhibited LBP·CD14-dependent transfer of endotoxin monomers derived from aggregates of tritiated lipooligosaccharide ([3H]LOS) from Neisseria meninigitidis to MD-2·TLR4, resulting in a reduced level of formation of a ([3H]LOS·MD-2·TLR4ECD)2 (Mr ∼ 190000) complex. This effect was due to inhibition of the transfer of [3H]LOS from aggregates in solution to sCD14 with little or no effect on [3H]LOS shuttling from [3H]LOS·sCD14 to MD-2. These compounds also inhibited transfer of the [3H]LOS monomer from full-length CD14 to a truncated, polyhistidine-tagged CD14. Dose-dependent inhibition of the transfer of [3H]LOS between the two forms of CD14 was observed with each of three different synthetic compounds that inhibited TLR4 activation but not by another structurally related analogue that lacked TLR4 antagonistic activity. Saturation transfer difference (STD) NMR data showed direct binding to CD14 by the synthetic TLR4 antagonist mediated principally through the lipid chains of the synthetic compound. Taken together, our findings strongly suggest that these compounds inhibit TLR4 activation by endotoxin by competitively occupying CD14 and thereby reducing the level of delivery of activating endotoxin to MD-2·TLR4.Keywords
This publication has 40 references indexed in Scilit:
- Analysis of binding site for the novel small‐molecule TLR4 signal transduction inhibitor TAK‐242 and its therapeutic effect on mouse sepsis modelBritish Journal of Pharmacology, 2009
- The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complexNature, 2009
- Isolation of Monomeric and Dimeric Secreted MD-2Journal of Biological Chemistry, 2008
- Glial TLR4 receptor as new target to treat neuropathic pain: Efficacy of a new receptor antagonist in a model of peripheral nerve injury in miceGlia, 2008
- Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide responseNature Immunology, 2006
- Endotoxin: physical requirements for cell activationInnate Immunity, 2005
- Endotoxin: physical requirements for cell activationInnate Immunity, 2005
- Crystal Structure of CD14 and Its Implications for Lipopolysaccharide SignalingJournal of Biological Chemistry, 2005
- An Essential Role for Albumin in the Interaction of Endotoxin with Lipopolysaccharide-binding Protein and sCD14 and Resultant Cell ActivationJournal of Biological Chemistry, 2002
- CD14, a Receptor for Complexes of Lipopolysaccharide (LPS) and LPS Binding ProteinScience, 1990